focus -WSS

focus

author：focus 2025-09-05 13:47:58 - browse：953

Adam's take main illustration — Molly Ferguson/STAT

Behind the stellar commercial launch of Amylyx Pharmaceuticals’ treatment for ALS lies an uncomfortable question: Does early success of the drug, called Relyvrio, make it more complicated, perhaps impossible, to pull it from the market if we find out next year that it doesn’t work?

On Monday night, Amylyx said Relyvrio sales totaled $22 million in 2022 — a period that covers slightly more than one calendar quarter given the drug’s U.S. approval last September. The company said approximately 1,300 ALS patients were on Relyvrio at the end of December, and it expects that number to at least double by the end of the first quarter.

“We’re probably going to double, closer to triple, our revenue in Q1,” said James Frates, Amylyx’s chief financial officer, speaking on Monday night’s conference call.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： FDA approval of Sarepta Duchenne genetic therapy gives me hope
Next article： Pregnant women don't need prenatal multivitamins, study concludes

Wikipedia

leisure time

WSS

Fetal cell organoids grown from amniotic fluid, study finds

Pregnant women don't need prenatal multivitamins, study concludes

Sanofi strikes deal with Novavax, boosting the vaccine maker

Bird flu outbreak in cows is latest avian flu curveball

It shouldn't be easy to buy synthetic DNA to recreate a deadly virus

Alcohol isn't healthy after all. Will new dietary guidelines reflect that?

hotspot

focus

focus

Tori Bowie and the unacceptable rates of Black maternal death

After gene therapy, two congenitally deaf children hear for the first time

Medical leaders decry Supreme Court decision on affirmative action

Change Healthcare: What is it, why does its cyberattack matter?

BioMarin wins approval for gene therapy to treat hemophilia A

For AI in health care standards, federal regulators join with industry group

Dobbs anniversary: the lost opportunity of abortion as health care

Apple Watch's A

Wildfire smoke exposes gaps in outdoor worker protections

Readout Newsletter: Sanofi, Novavax, Maze x Shionogi news

focus

Medicare drug price negotiation hearing pits pharma v Biden admin

Researchers on aging grapple with how to calculate biological age

For AI in health care standards, federal regulators join with industry group

H5N1 communication has been strictly for the birds

IVF doctors demand details after CooperSurgical lawsuit

It shouldn't be easy to buy synthetic DNA to recreate a deadly virus

Wikipedia

leisure time

leisure time

knowledge